Education
About Us
Working with TipRanks
Follow Us
Aroa Biosurgery Ltd (AU:ARX)
ASX:ARX
ARX Stock Chart & Stats
AU$0.70
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.70
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$0.80
Previous CloseN/A
Volume195.72K
Average Volume (3M)302.12K
Market Cap
AU$243.56M
Enterprise ValueAU$240.55M
Total Cash (Recent Filing)AU$20.71M
Total Debt (Recent Filing)AU$6.14M
Price to Earnings (P/E)―
Beta0.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding345,476,200
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)1.73
Price to Sales (P/S)1.90
P/FCF Ratio-25.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.85Price Target Upside21.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~17% revenue growth reflects expanding clinical adoption of Aroa's ECM products across wound care and reconstructive applications. Over 2–6 months this trend supports scale benefits, broader payer/provider familiarity and provides a larger base to convert operating leverage into margin and cash‑flow improvements.
Balance Sheet StrengthA high equity ratio and low leverage give the company financial flexibility to invest in commercialization, R&D and inventory without immediate refinancing. This durability reduces bankruptcy and liquidity risk, allowing management to sustain growth investments while operating losses are resolved.
Improving ProfitabilityA strong gross margin combined with a shift to positive EBITDA demonstrates operational improvements and emerging unit economics. If sustained by revenue growth, this structural improvement supports a credible path from loss-making to cash-generative operations and reduces reliance on external capital over the medium term.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow constrains the firm's ability to self-fund growth, capex and working capital needs. Over several months this raises the likelihood of external financing, which can dilute shareholders or increase interest burden, and limits nimbleness in scaling commercial efforts.
Persistent Net Losses / Negative ROEOngoing net losses producing negative ROE indicate equity capital is not yet generating returns. Structurally this heightens pressure for either sustained margin improvement or additional capital raises, and weakens long‑term shareholder value creation until profitability consistently materializes.
Demand & Channel SensitivityRevenue dependence on procedure volumes and third‑party distribution exposes Aroa to structural risks: shifts in hospital utilization, reimbursement changes, or distributor concentration can materially affect sales. Diversifying channels and indications is needed to reduce this durable demand sensitivity.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.35 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$243.56M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Currently, no data Available
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,476,200 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.85 (21.43% Upside)
AU$0.85 (21.43% Upside)
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
-2.01%
Trailing 12-Months
Asset Growth
-2.82%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
ARX Stock 12 Month Forecast
Average Price Target
AU$0.85
▲(21.43% Upside)
Technical Analysis
Polynovo
―
Cochlear
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---